ZYDUSLIFE

While the broader indices are feeling the heat of global geopolitical tensions, the Pharma sector is acting as a defensive shield. Leading the pack with fresh news is Zydus Lifesciences. The company just announced a major regulatory win. Its Unit 9 (Ahmedabad) injectable facility successfully cleared a USFDA Pre-Approval Inspection (PAI) with NIL (Zero) observations. For a pharma giant, a "Zero Observation" report is the gold standard. It paves the way for faster drug approvals in the lucrative US market, especially for high-margin injectables. Fundamentals P/E Ratio: ~18.5 (Trading at a discount compared to the industry median of ~27). ROE: Healthy at 21.2%. New Launch: The company also recently launched ANYRA, India’s first indigenous biosimilar for retinal disorders. Technical Setup (For the Chart Watchers): Support: The stock has strong psychological and volume-based support near the ₹895–₹900 zone. Resistance: Immediate resistance is visible at ₹915. A sustained move above this could open doors for the ₹930+ levels seen in the derivatives data. RSI: Currently hovering in the 55-60 range—indicating "Positive Momentum" without being overbought. This post is for educational purposes only and does not constitute financial advice or a recommendation to buy/sell.